[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-lower-extremity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-lower-extremity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100638299","assessment-of-the-efficacy-of-the-dynamic-decongestive-system-in-the-maintenance-phase-of-lower-limb-lymphedema-100638299",false,"NCT07603531","Assessment of the Efficacy of the Dynamic Decongestive System in the Maintenance Phase of Lower Limb Lymphedema","A Multicenter Controlled Randomised Clinical Trial to Assess the Efficacy of the Dynamic Decongestive System During the Maintenance Phase of Lower Limb Lymphedema Treatment","EDYDES-maint","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Men and women\n* Unilateral lower limb lymphedema of stage II or III according to the criteria defined by the International Society of Lymphology\n* Patients completing an inpatient intensive treatment phase, including patients participating in CIV-25-01-050914, with a minimum of 20% of excess volume reduction\n* Patients who have given their informed consent freely and signed it prior to any intervention in the study.\n* Patients with a morphology compatible with the perimetric coverage of the device (calf and thigh).\n* Patients able to use the device\n* Patients enrolled in a social security plan or covered by similar health insurance.\n\nExclusion Criteria:\n\n* Patients with suspended lymphoedema of the thigh (unaffected calf and foot)\n* Patients with lipedema\n* Patients with bilateral lower limb lymphoedema\n* Patients with a lymphedema associated with active cancer requiring acute chemotherapy, or oncologic relapses, or treatment in progress\n* Patients with contraindications for compression on the lower limbs such as stent\u002Farterial graft in the area under compression\n* Peripheral artery disease ABI ≤ 0.6\n* Advanced diabetic microangiopathy\n* Active deep\u002Fsuperficial active or recent venous thrombosis, phlegmasia ceruela dolens (painful blue inflammation), active venous leg ulcers, septic\u002Facute thrombophlebitis of the limb (in the last 6 months)\n* A condition where increased venous or lymphatic return is undesirable\n* Neurological disease (including neurogenic diabetic foot, severe peripheral neuropathy of the limb)\n* Pulmonary embolism (last 6 months), pulmonary edema, poorly controlled asthma\n* Cardiac insufficiency (compensated or decompensated)\n* Implantable stimulation devices such as pacemaker\n* Chronic kidney disease with acute renal failure\n* Open skin lesions or skin and subcutaneous infection (cellulitis, erysipelas, lymphangitis, etc.)\n* Skin atrophy of the limb\n* Bullous dermatoses\n* Presence of subcutaneous osteosynthesis material with an external component lying subdermally at the level of the treated lower limb\n* Hyperalgesia of the foot, knee or hip\n* Patients with a known allergy to the components used in the device\n* Patients with psychiatric, psychological, or neurological disorders\n* Patients with impaired cognitive or motor skills and dependent individuals\n* Patients participating in another clinical trial\n* Pregnant or breastfeeding women. Women of childbearing potential will undergo Clearblue® urine pregnancy testing prior to enrollment to verify eligibility.\n* Vulnerable patients, adults being the object of a legal protective measure or unable to express their consent\n* Patients unable to submit to the constraints of the protocol","ALL","18 Years",{"count":20,"type":21},98,"ESTIMATED","INTERVENTIONAL",[24],"NA","The trial aims to determine whether the dynamic compression device, used in combination with elastic compression garments, is non-inferior to currently available compression devices (CACD) during the maintenance phase of lower-limb lymphoedema treatment.\n\nThis is a two-arm, parallel-group trial. Both groups will include patients being discharged after the inpatient intensive treatment phase for lower-limb lymphoedema. Eligible participants will be enrolled on the afternoon of their final inpatient treatment day, prior to discharge.\n\nParticipants will be allocated to one of the following groups:\n\nDDS group: elastic compression garment worn at least during the day and as often as possible during the night, according to patient preference and expert advice, plus DDS use for a minimum of 2 hours at the end of the day, used alone without an elastic garment.\n\nControl group: elastic compression garment worn at least during the day and as often as possible during the night, according to patient preference and expert advice, plus currently available compression devices, including multicomponent bandages, pneumatic compression devices, and compression wraps, according to patient preference and the center's recommendations.\n\nManual lymphatic drainage will be permitted in both groups.\n\nPatients will undergo three assessment visits:\n\nVisit 1 \u002F Baseline-Inclusion (V1): afternoon of the final inpatient treatment day, prior to discharge from intensive treatment; Visit 2 (V2): end of week 6, ± 7 days; Visit 3 (V3): end of week 12, ± 7 days.",[27],"Lymphedema Lower Extremity",[29,30,31,32,33,34],"Complex decongestive therapy","Dynamic compression","Non-inferiority trial","Lymphoedema maintenance treatment","Limb volume reduction","Limb volume maintenance","NOT_YET_RECRUITING","2026-05-27",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2027-09-30",{"name":45,"class":46},"Jean-Paul Belgrado","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100637615","assessment-of-the-efficacy-of-the-dynamic-decongestive-system-in-the-intensive-phase-of-lower-limb-lymphedema-100637615","NCT07622615","Assessment of the Efficacy of the Dynamic Decongestive System in the Intensive Phase of Lower Limb Lymphedema","A Multicenter Controlled Randomised Clinical Trial to Assess the Efficacy of the Dynamic Decongestive System During the Intensive Phase of Lower Limb Lymphedema Treatment","EDYDES-int","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Men and women\n* Unilateral lower limb lymphoedema of stage II or III according to the criteria defined by the International Society of Lymphology\n* Relative volume difference between affected and healthy leg ≥ 10%\n* Patients requiring intensive decongestive treatment in a hospital setting\n* Patients who have given their informed consent freely and signed it prior to any intervention in the study.\n* Patients with a morphology compatible with the perimetric coverage of the device (calf and thigh).\n* Patients able to use the device\n* Patients enrolled in a social security plan or covered by similar health insurance.\n\nExclusion Criteria:\n\n* Patients with suspended lymphoedema of the thigh (unaffected calf and foot)\n* Patients with lipedema\n* Patients with bilateral lower limb lymphoedema\n* Patients with a lymphoedema associated with active cancer requiring acute chemotherapy, or oncologic relapses, or treatment in progress\n* Patients with contraindications for compression on the lower limbs such as stent\u002Farterial graft in the area under compression\n* Peripheral artery disease ABI ≤ 0.6\n* Advanced diabetic microangiopathy\n* Deep\u002FSuperficial active or recent venous thrombosis, phlegmasia ceruela dolens (painful blue inflammation), septic\u002Facute thrombophlebitis of the limb (in the last 6 months), active venous leg ulcers\n* A condition where increased venous or lymphatic return is undesirable\n* Neurological disease (including neurogenic diabetic foot, severe peripheral neuropathy of the limb)\n* Pulmonary embolism (last 6 months)\n* Pulmonary edema\n* Cardiac insufficiency (compensated or decompensated)\n* Implantable stimulation devices such as pacemaker\n* Chronic kidney disease with acute renal failure\n* Epilepsy\n* Poorly controlled asthma\n* Open skin lesions or skin and subcutaneous infection (cellulitis, erysipelas, lymphangitis, etc.)\n* Skin atrophy of the limb\n* Bullous dermatoses\n* Presence of subcutaneous osteosynthesis material with an external component lying subdermally at the level of the treated lower limb\n* Hyperalgesia of the foot, knee or hip\n* Patients with a known allergy to the components used in the device\n* Patients with psychiatric, psychological, or neurological disorders\n* Patients with impaired cognitive or motor skills and dependent individuals\n* Patients participating in another clinical trial\n* Pregnant or breastfeeding women\n* Vulnerable patients, adults being the object of a legal protective measure or unable to express their consent\n* Patients unable to submit to the constraints of the protocol",{"count":56,"type":21},110,[24],"The goal of this study is to compare the efficacy of a dynamic compression device (DDS) with traditional multicomponent bandages (TMCB) in terms of excess volume reduction in lower limb lymphoedema during the first 5 days of intensive treatment.\n\nParticipants in both groups will undergo the standard decongestive treatment protocol of the trial site. The only difference between both groups will be the modality of the compression therapy:\n\n* the intervention (DDS) group will wear the compression 24\u002F24 during the first 5 days of intensive treatment\n* the control group will wear TMCB 24\u002F24 during the first 5 days of intensive treatment (i.e. the standard treatment)",[27],[29,30,31,32,33,34],{"date":62,"type":39},"2026-06-03",{"date":41,"type":21},{"date":65,"type":21},"2027-12-30",{"name":45,"class":46},{"id":68,"slug":4,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100624821","NCT07414615","Aerobic Training in Lower Extremity Lymphedema","The Effect of Aerobic Training on Gait, Postural Control, Lower Extremity Muscle Strength and Functionality in Patients With Lower Extremity Lymphedema","Inclusion Criteria:\n\n* Aged between 20 and 60 years\n* Diagnosed with bilateral lower extremity lymphedema\n* Completion of chemotherapy, radiotherapy, or other oncological treatments, with no oncological contraindication to participation\n* Signed written informed consent\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Presence of uncontrolled cardiac or pulmonary disease\n* Presence of renal insufficiency\n* Presence of musculoskeletal or neurological disorders affecting mobility or balance\n* Presence of systemic or local infection in the lower extremity\n* Impaired independent ambulation or use of assistive walking devices\n* Pregnancy\n* Presence of visual, cognitive, or intellectual impairment that may interfere with participation in assessment or intervention procedures","20 Years","60 Years",{"count":76,"type":21},24,[24],"This randomized controlled study aims to evaluate the effects of aerobic exercise training on gait, postural control, lower extremity muscle strength, and functional status in individuals with bilateral lower extremity lymphedema. A total of 24 participants aged between 20 and 60 years with a diagnosis of bilateral lower extremity lymphedema will be randomly assigned to either an aerobic exercise group or a control group. The aerobic exercise group will receive aerobic exercise training in addition to Complex Decongestive Therapy (CDT), while the control group will receive CDT alone.\n\nLower extremity edema will be assessed using circumferential measurements taken from the ankle to the inguinal region. Gait function will be evaluated through angular and spatiotemporal analysis using Kinovea software, including parameters such as step length, walking speed, and double support time. Postural control will be assessed using the Balance Error Scoring System (BESS) and the Timed Up and Go Test. Lower extremity muscle strength and endurance will be evaluated using Manual Muscle Testing and the 30-Second Sit-to-Stand Test. Functional status of the lower extremities will be assessed using the Lower Extremity Functional Scale (LEFS).",[80,27],"Lymphedema",[80,82,83,84,85,86],"Lower Extremity","Gait","Postural Control","Muscle Strength","Functionality","RECRUITING","2026-02-17",{"date":90,"type":39},"2026-02-19",{"date":92,"type":39},"2026-02-16",{"date":94,"type":21},"2026-04-10",{"name":96,"class":46},"Bezmialem Vakif University",1]